CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.
暂无分享,去创建一个
A. Pettitt | M. Pirmohamed | D. Catovsky | D. Oscier | D. Carr | R. Eccles | Laura-Jayne Gardiner | D. Gonzalez de Castro | T. Cox | J. Strefford | Ke Lin | D. Sibson | B. Lloyd | M. Oates | M. Else | G. Johnson
[1] Ulrich M. Zanger,et al. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance , 2013, Front. Genet..
[2] G. Morgan,et al. CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes , 2013, Haematologica.
[3] D. Catovsky,et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. , 2013, Blood.
[4] D. Catovsky,et al. The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry , 2012, Leukemia.
[5] M. Dyer,et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Pettitt,et al. Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration , 2012, Clinical Cancer Research.
[7] A. Pettitt,et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Stoneking,et al. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. , 2012, Pharmacogenomics.
[9] Takuya Kumamoto,et al. Q172H Replacement Overcomes Effects on the Metabolism of Cyclophosphamide and Efavirenz Caused by CYP2B6 Variant with Arg262 , 2011, Drug Metabolism and Disposition.
[10] Š. Pospíšilová,et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Morgan,et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Hallek,et al. Prognostic factors in chronic lymphocytic leukemia—what do we need to know? , 2011, Nature Reviews Clinical Oncology.
[13] J. Ritz,et al. Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation , 2010, American journal of hematology.
[14] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[15] D. Catovsky,et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation , 2010, Haematologica.
[16] H. Döhner,et al. From pathogenesis to treatment of chronic lymphocytic leukaemia , 2010, Nature Reviews Cancer.
[17] Wei Duan,et al. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. , 2009, Current drug metabolism.
[18] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[19] M. Schwab,et al. Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver , 2008, Journal of Pharmacology and Experimental Therapeutics.
[20] T Hamblin,et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.
[21] M. Schwab,et al. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. , 2007, Pharmacogenomics.
[22] Lang Li,et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. , 2007, Pharmacogenomics.
[23] H. Mukai,et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients , 2007, Pharmacogenetics and genomics.
[24] M Schwab,et al. Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals , 2007, Clinical pharmacology and therapeutics.
[25] M. Grever,et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] G. Brittinger,et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.
[27] N. Chiorazzi,et al. mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .
[28] S. Rodenhuis,et al. Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.
[29] U. Yasar,et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation , 2003, The Pharmacogenomics Journal.
[30] D. Waxman,et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[31] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[32] B. Cheson,et al. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Robert A. Maxwell,et al. Drug Discovery: A Casebook and Analysis , 1990 .
[34] T. A. Connors,et al. Aryl-2-halogenoalkylamines. XXV. Derivatives of sulphanilamide designed for selective deposition in neoplastic tissue. , 1968, European journal of cancer.
[35] J. Roberts,et al. 486. Aryl-2-halogenoalkylamines. Part XII. Some carboxylic derivatives of NN-di-2-chloroethylaniline , 1953 .